Friday, Sep 25, 2020 | Last Update : 03:36 AM IST

184th Day Of Lockdown

Maharashtra126379995603033015 Andhra Pradesh6543855794745410 Tamil Nadu5636915082108871 Karnataka5485574446588331 Uttar Pradesh3588932895945135 Delhi2492592133045014 West Bengal2283021989834421 Odisha184122149379763 Telangana1792461481391070 Bihar169856155824870 Assam159320129130578 Kerala13863398720554 Gujarat1247671051913337 Rajasthan116881972841352 Haryana113075908841177 Madhya Pradesh108167836182007 Punjab99930754092860 Chhatisgarh8618347653680 Jharkhand7267358543626 Jammu and Kashmir65026421151024 Uttarakhand4177729000501 Goa2875322726360 Puducherry2319118065467 Tripura2227215441245 Himachal Pradesh124387836125 Chandigarh102987411123 Manipur9010683859 Arunachal Pradesh7385540813 Nagaland5544445110 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  Business   Companies  05 Aug 2020  Lupin launches Covihalt at Rs 49 per tablet for COVID treatment

Lupin launches Covihalt at Rs 49 per tablet for COVID treatment

PTI
Published : Aug 5, 2020, 3:30 pm IST
Updated : Aug 5, 2020, 3:30 pm IST

Favipiravir has received authorisation from the Drug Controller General of India for emergency use, Lupin said

 Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet. (Representative Image)
  Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet. (Representative Image)

New Delhi: Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name 'Covihalt' for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

 

Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.

Lupin President - India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.

On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ''FluGuard'' for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.

 

Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE.

Tags: lupin, lupin favipiravir, favipiravir by lupin, lupin launches favipiravir, lupin favipiravir price
Location: India, Delhi, New Delhi